BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-07-21 05:00 |
BERGENBIO COVID-19 DATA PRESENTED AT THE ANNUAL AMERICAN SOCIETY FOR VIROLOGY
|
English | 191.2 KB | ||
| 2021-07-21 05:00 |
BERGENBIO COVID-19 DATA PRESENTED AT THE ANNUAL AMERICAN SOCIETY FOR VIROLOGY
|
English | 6.5 KB | ||
| 2021-07-12 12:12 |
BERGENBIO PRESENTS ENCOURAGING COMBINED DATA FOR BEMCENTINIB FROM TWO PHASE II …
|
English | 239.8 KB | ||
| 2021-07-12 12:12 |
BERGENBIO PRESENTS ENCOURAGING COMBINED DATA FOR BEMCENTINIB FROM TWO PHASE II …
|
English | 10.3 KB | ||
| 2021-07-10 11:00 |
PRECLINICAL BEMCENTINIB AND TILVESTAMAB DATA PRESENTED AT EAU 2021
|
English | 186.7 KB | ||
| 2021-07-10 11:00 |
PRECLINICAL BEMCENTINIB AND TILVESTAMAB DATA PRESENTED AT EAU 2021
|
English | 6.1 KB | ||
| 2021-06-29 05:00 |
BERGENBIO PRESENTING COVID-19 DATA IN LATE-BREAKING ABSTRACT PRESENTATION AT EC…
|
English | 186.1 KB | ||
| 2021-06-29 05:00 |
BERGENBIO PRESENTING COVID-19 DATA IN LATE-BREAKING ABSTRACT PRESENTATION AT EC…
|
English | 6.7 KB | ||
| 2021-06-28 05:00 |
BERGENBIO TO PRESENT AT 4th ANNUAL NEXT GEN IMMUNO-ONCOLOGY VIRTUAL CONGRESS
|
English | 182.2 KB | ||
| 2021-06-28 05:00 |
BERGENBIO TO PRESENT AT 4th ANNUAL NEXT GEN IMMUNO-ONCOLOGY VIRTUAL CONGRESS
|
English | 5.8 KB | ||
| 2021-06-16 10:41 |
BerGenBio ASA: Share capital increase
|
Norwegian | 121.7 KB | ||
| 2021-06-16 10:41 |
BerGenBio ASA: Share capital increase
|
Norwegian | 1.9 KB | ||
| 2021-06-11 18:24 |
BerGenBio ASA: Increase of share capital, exercise of share options and disclos…
|
English | 207.0 KB | ||
| 2021-06-11 18:24 |
BerGenBio ASA: Increase of share capital, exercise of share options and disclos…
|
English | 85.5 KB | ||
| 2021-06-11 18:24 |
BerGenBio ASA: Increase of share capital, exercise of share options and disclos…
|
English | 2.9 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
